Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 15/20 | 1.00 |
| ▸ | MCTS1 | Q9ULC4 | 10/20 | 0.55 |
| ▸ | SLC16A1 | P53985 | 9/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bindarit SCHEMBL29387325 | 1.00 | SLC16A3 (1.00) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| Bindarit SCHEMBL371677 | 0.99 | SLC16A3 (0.98) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL928717 | 0.93 | SLC16A3 (0.87) | SLC16A3MCTS1SLC16A1HDAC3HDAC1 | |
| SCHEMBL928508 | 0.93 | SLC16A3 (0.87) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL15372292 | 0.92 | SLC16A3 (0.84) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL927983 | 0.91 | SLC16A3 (0.83) | SLC16A3MCTS1SLC16A1CNR1CNR2 | |
| SCHEMBL1650741 | 0.91 | SLC16A3 (0.83) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL927364 | 0.90 | SLC16A3 (0.81) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL927459 | 0.90 | SLC16A3 (0.81) | SLC16A3MCTS1SLC16A1CNR1ACHE | |
| SCHEMBL927411 | 0.89 | SLC16A3 (0.80) | SLC16A3MCTS1SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007636-A1 | TREATING VASCULAR STENOSIS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2026-01-08 | — | — | US | claimed |
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | TRANSLATUM MEDICUS INC (CA) | 2026-01-08 | — | — | US | claimed |
| EP-4662203-A1 | BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS | Translatum Medicus Inc. (CA) | 2025-12-17 | — | — | EP | claimed |
| US-12465605-B2 | Methods and materials for gender-dependent treatment of cardiovascular dysfunction | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-11-11 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | Translatum Medicus Inc. (CA) | 2025-08-05 | — | — | US | claimed |
| US-20250179166-A1 | TREATMENT OF BRAIN METASTASIS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-06-05 | — | — | US | claimed |
| EP-4547286-A1 | TREATING VASCULAR STENOSIS | Mayo Foundation for Medical Education and Research (US) | 2025-05-07 | — | — | EP | claimed |
| CN-119235817-B | Anti-inflammatory nano drug-carrying system containing guanidine structure, and preparation method and application thereof | 南昌大学第二附属医院 | 2025-03-21 | — | — | CN | claimed |
| CN-119235817-A | Anti-inflammatory nano drug-carrying system containing guanidine structure, and preparation method and application thereof | 南昌大学第二附属医院 | 2025-01-03 | — | — | CN | claimed |
| US-6319517-B1 | TREHALOSE ADDED TO THE OUTSIDE OF THE LIPOSOMES ALREADY FORMED BEFORE LYOPHILIZATION; STABILITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2001-11-20 | — | — | US | claimed |
| CN-1255057-A | Aqueous pharmaceutical composition containing active ingredient extremely poorly soluble in water | ANGELINI RICERCHE SPA (IT) | 2000-05-31 | — | — | CN | claimed |
| CN-1248163-A | Pharmaceutical preparation containing lyophilized liposomes encapsulating a poorly water-soluble active ingredient and process for preparing the same | ANGELINI RICERCHE SPA (IT) | 2000-03-22 | — | — | CN | claimed |
| EP-0981332-A1 | PHARMACEUTICAL PREPARATION COMPRISING LYOPHILIZED LIPOSOMES ENCAPSULATING AN ACTIVE PRINCIPLE WHICH IS HIGHLY INSOLUBLE IN WATER, AND THE PROCESS FOR PREPARING THE SAID PREPARATION | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2000-03-01 | — | — | EP | claimed |
| US-6020356-A | SYNERGISTIC MIXTURE OF BINDARIT, IMMUNOSUPPRESSANT AND EXCIPIENT | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 2000-02-01 | — | — | US | claimed |
| EP-0973505-A1 | AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT WHICH IS HIGHLY INSOLUBLE IN WATER | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO - A.C.R.A.F. - S.p.A. (IT) | 2000-01-26 | — | — | EP | claimed |
| WO-1998036735-A1 | AQUEOUS PHARMACEUTICAL COMPOSITION COMPRISING AN ACTIVE INGREDIENT WHICH IS HIGHLY INSOLUBLE IN WATER | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. SPA (IT) | 1998-08-27 | — | — | WO | claimed |
| WO-1998036736-A1 | PHARMACEUTICAL PREPARATION COMPRISING LYOPHILIZED LIPOSOMES ENCAPSULATING AN ACTIVE PRINCIPLE WHICH IS HIGHLY INSOLUBLE IN WATER, AND THE PROCESS FOR PREPARING THE SAID PREPARATION | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1998-08-27 | — | — | WO | claimed |
| EP-0858337-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1998-08-19 | — | — | EP | claimed |
| WO-1997016185-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 1997-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007778-A1 | METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES | AGER, ALDH1A2, RBP1 | SLC16A3 1633/4885MCTS1 3063/4885SLC16A1 852/4885 |
| US-20250179166-A1 | TREATMENT OF BRAIN METASTASIS | CCR4, CCR1, CCR3 | SLC16A3 268/4885MCTS1 166/4885SLC16A1 285/4885 |
| US-20260007636-A1 | TREATING VASCULAR STENOSIS | CCL2, SELL, VCAM1 | SLC16A3 102/4885MCTS1 482/4885SLC16A1 74/4885 |
| US-12377171-B2 | Methods for treating and diagnosing blinding eye diseases | ALDH1A2, RBP1, RBP4 | SLC16A3 4131/4885MCTS1 3508/4885SLC16A1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.